Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at kontrollere leversundheden hos drenge med XLMTM, en alvorlig genetisk muskeltilstand (EXCEL)

29. september 2026 opdateret af: Astellas Gene Therapies

En ikke-interventionel, epidemiologisk undersøgelse af XLMTM og klinisk udtryk i leveren

XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.

Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.

There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).

In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.

This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

50

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada
        • Rekruttering
        • Site CA15001
      • Leeds, Det Forenede Kongerige
        • Rekruttering
        • Site GB44006
      • London, Det Forenede Kongerige
        • Rekruttering
        • Site GB44003
      • Oxford, Det Forenede Kongerige
        • Rekruttering
        • Site GB44005
    • California
      • Santa Monica, California, Forenede Stater, 90401-2072
        • Rekruttering
        • UCLA Neurological Services
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Boston Children's Hospital
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Rekruttering
        • UPMC Children's Hospital of Pittsburgh
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • University of Utah

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

Ikke ældre end 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.

Beskrivelse

Inclusion Criteria:

  • Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
  • Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
  • Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.

Exclusion Criteria:

  • Participant is currently enrolled in an interventional study designed to treat XLMTM.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Participants with XLMTM

Pediatric and adolescent participants with XLMTM.

No investigational drug will be administered to participants in this study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence rate of cholestasis
Tidsramme: Up to Week 48

Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.

Up to Week 48
Point prevalence of cholestasis
Tidsramme: Day 1

Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).

Day 1
Prevalence of cholestasis
Tidsramme: Up to 1 year

Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).

Up to 1 year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Genetic variants of MTM1
Tidsramme: Up to Week 48

The association between genetic variants of MTM1 and cholestasis will be evaluated.

Up to Week 48
Risk of cholestasis temporarily associated with environmental modifiers
Tidsramme: Up to Week 48

Medication use, immunization history, infectious disease history and dietary habits will be collected.

Up to Week 48
Hospitalizations
Tidsramme: Up to Week 48

Frequency and reason for hospitalizations will be collected.

Up to Week 48
Duration of Hospitalizations
Tidsramme: Up to Week 48

Duration of hospitalization visits will be collected.

Up to Week 48
Emergency room visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Hepatology specialist visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Scheduled/unscheduled office visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Non-study-specified home healthcare visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Surgeries/procedures
Tidsramme: Up to Week 48

Frequency and type will be collected.

Up to Week 48

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Medical Director, Astellas Gene Therapies

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. maj 2025

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

19. august 2024

Først indsendt, der opfyldte QC-kriterier

29. august 2024

Først opslået (Faktiske)

3. september 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • 1600-MA-3536

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .